https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-21 / Expert Rev Anticancer Ther 2014 Jul;14(7):761-3
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-21 / Expert Rev Anticancer Ther 2014 Jul;14(7):761-32014-05-21 00:00:002019-02-15 08:46:21Dendritic cell immunotherapy for glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-13 / J Immunother Cancer 2014;2:10
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-13 / J Immunother Cancer 2014;2:102014-05-13 00:00:002019-02-15 08:46:23Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-01 / Future Oncol 2014 May;10(6):911-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-01 / Future Oncol 2014 May;10(6):911-52014-05-01 00:00:002019-02-15 08:46:22Immunotherapy for high-grade glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-04-03 / J Immunol Res 2014;2014:796856
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-04-03 / J Immunol Res 2014;2014:7968562014-04-03 00:00:002019-02-15 08:46:25Current vaccine trials in glioblastoma: a review
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-03-01 / Discov Med 2014 Mar;17(93):145-54
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-03-01 / Discov Med 2014 Mar;17(93):145-542014-03-01 00:00:002019-02-15 08:46:25Novel approaches and mechanisms of immunotherapy for glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-02-18 / J Immunother Cancer 2014;2:4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-02-18 / J Immunother Cancer 2014;2:42014-02-18 00:00:002019-02-15 08:46:24Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-02-01 / Anticancer Res. 2014 Feb;34(2):565-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-02-01 / Anticancer Res. 2014 Feb;34(2):565-742014-02-01 00:00:002014-02-01 00:00:00Fighting fire with fire: the revival of thermotherapy for gliomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-11-12 / Expert Rev Neurother 2013 Dec;13(12):1395-406
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-11-12 / Expert Rev Neurother 2013 Dec;13(12):1395-4062013-11-12 00:00:002021-11-15 13:32:44Myeloid-derived suppressor cells in glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-11-01 / Neurosurgery 2013 Nov;73(5):863-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-11-01 / Neurosurgery 2013 Nov;73(5):863-72013-11-01 00:00:002019-02-15 08:46:26Dendritic cell vaccine for recurrent high-grade gliomas in pediatric and adult subjects: clinical trial protocol
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-10-21 / Neurol. Med. Chir. (Tokyo) 2013;53(11):741-54
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-10-21 / Neurol. Med. Chir. (Tokyo) 2013;53(11):741-542013-10-21 00:00:002019-02-15 08:47:29Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials
